CIK 0001652130
- Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 364785571
- Phone
- +1 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +9,943 | 131,192 | ||
| 2026-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +14,204 | 14,204 | ||
| 2026-01-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −11,903 | $9.21 | $110K | 121,249 |
| 2025-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +43,200 | 130,866 | ||
| 2025-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +61,714 | 61,714 | ||
| 2025-01-03 | Lebwohl David EVP, Chief Medical Officer | Sale | −9,557 | $12.18 | $116K | 87,666 |
| 2025-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,189 | 97,223 | ||
| 2025-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,189 | 0 | ||
| 2024-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +38,701 | 93,073 | ||
| 2024-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +55,855 | 55,855 | ||
| 2024-01-03 | Lebwohl David EVP, Chief Medical Officer | Sale | −5,843 | $29.46 | $172K | 54,372 |
| 2024-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,187 | 60,215 | ||
| 2024-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,187 | 3,189 | ||
| 2023-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +30,674 | 56,361 | ||
| 2023-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +43,342 | 43,342 | ||
| 2023-01-04 | Lebwohl David EVP, Chief Medical Officer | Sale | −2,574 | $37.21 | $96K | 25,687 |
| 2023-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise | +3,187 | 28,261 | ||
| 2023-01-01 | Lebwohl David EVP, Chief Medical Officer | Option exercise · Restricted Stock Unit | −3,187 | 6,376 | ||
| 2022-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +20,203 | 20,203 | ||
| 2022-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +13,816 | 24,738 |
Page 1 of 3 · 55 trades